Literature DB >> 17278263

Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders.

Felix Agbalika1, Jerome Larghero, Helene Esperou, Dominique Marais, Marie Robin, Elena Foïs, Régis Peffault de Latour, Eliane Gluckman, Vanderson Rocha, Marc Benbunan, Gerard Socié, Jean-Pierre Marolleau.   

Abstract

The occurrence of post-transplant lymphoproliferative disorders (PTLDs) after allogeneic haematopoietic stem cell transplantation (allo-HSCT) represents a clinical problem. Pretransplant Epstein-Barr virus serological status and viral load was determined in 21 recipients and 28 control transplanted patients, with (+) and without (-) PTLD, respectively. Early-antigen immunoglobulin G (EA-IgG) was detected in 12/21 PTLD+ patients, but only 2/28 PTLD patients (P = 0.00023, Odds ratio = 17.42). High viral load was detected in peripheral blood mononuclear cells at PTLD diagnosis, independently of deleted LMP1. Detection of EA-IgG in allo-HSCT recipients pretransplantation might be considered as risk factor for PTLD development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17278263     DOI: 10.1111/j.1365-2141.2006.06420.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Epstein-Barr virus infection after unrelated cord blood transplantation: reactivation or reinfection?

Authors:  Keisei Kawa; Akihisa Sawada; Maho Koyama; Masami Inoue
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

Review 2.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.

Authors:  L Rasche; M Kapp; H Einsele; S Mielke
Journal:  Bone Marrow Transplant       Date:  2013-07-08       Impact factor: 5.483

3.  Investigation of epstein-barr virus and parvovirus b19 DNA in allogeneic stem cell transplant patients.

Authors:  Altay Atalay; Selma Gökahmetoğlu; Süleyman Durmaz; Idris Kandemir; Derya Sağlam; Leylagül Kaynar; Bülent Eser; Mustafa Cetin; Hüseyin Kılıç
Journal:  Turk J Haematol       Date:  2014-06-10       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.